Non Small Cell Lung Cancer Clinical Trials

204 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Toronto, Ontario

   Locations

   38 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

2. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

   This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health, Tucson, Arizona

   Locations

   14 in total

   Run by

   Obsidian Therapeutics, Inc.

   See if you can join NCT06060613 on ClinicalTrials.gov

3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   21 in total

   Run by

   Gilead Sciences

   See if you can join NCT06303505 on ClinicalTrials.gov

4. A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

   To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07133425 on ClinicalTrials.gov

5. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

   The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor?…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   14 in total

   Run by

   Kumquat Biosciences Inc.

   See if you can join NCT07542704 on ClinicalTrials.gov

6. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

   The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California San Diego Moores Cancer Center, La Jolla, California

   Locations

   24 in total

   Run by

   Teligene US

   See if you can join NCT06010329 on ClinicalTrials.gov

8. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham, Alabama

   Locations

   366 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

9. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

   Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. Jude Medical Center, Fullerton, California

   Locations

   141 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07185997 on ClinicalTrials.gov

10. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    ClinRé 001-022 (Premier Cancer Care and Infusion Center), Fresno, California

    Locations

    203 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT07195695 on ClinicalTrials.gov

11. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radi…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Low Country Cancer Care ( Site 0155), Savannah, Georgia

    Locations

    107 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07554339 on ClinicalTrials.gov

12. Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

    The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a spe…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT01639508 on ClinicalTrials.gov

13. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs…

    Stage

    Phase 2

    Ages

    18 to 72

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03412877 on ClinicalTrials.gov

14. Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

    In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Stanford, California

    Run by

    Stanford University

    See if you can join NCT04585477 on ClinicalTrials.gov

15. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    32 in total

    Run by

    Pierre Fabre Medicament

    See if you can join NCT06043817 on ClinicalTrials.gov

16. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prev…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento, California

    Locations

    124 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07513376 on ClinicalTrials.gov

17. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    City of Hope /ID# 243157, Duarte, California

    Locations

    317 in total

    Run by

    AbbVie

    See if you can join NCT04928846 on ClinicalTrials.gov

18. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arizona Cancer Center, Tucson, Arizona

    Locations

    60 in total

    Run by

    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

19. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    CARTI Cancer Center ( Site 0006), Little Rock, Arkansas

    Locations

    217 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06422143 on ClinicalTrials.gov

20. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Tucson, Arizona

    Locations

    333 in total

    Run by

    AstraZeneca

    See if you can join NCT06692738 on ClinicalTrials.gov

21. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St. Elizabeth Healthcare, Edgewood, Kentucky

    Locations

    17 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

22. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA Santa Monica Hematology Oncology, Santa Monica, California

    Locations

    22 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

23. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    85 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT04886804 on ClinicalTrials.gov

24. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    12 in total

    Run by

    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

25. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Anchorage, Alaska

    Locations

    290 in total

    Run by

    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov